HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

INDQ/NO, a bioreductively activated nitric oxide prodrug.

Abstract
The design, synthesis, and development of INDQ/NO, a novel nitric oxide (NO) prodrug targeted by a bioreductive trigger, are described. INDQ/NO, an indolequinone-diazeniumdiolate is found to be metabolized to produce NO by DT-diaphorase, a bioreductive enzyme that is overexpressed in certain cancers and hypoxic tumors. Cell-based assays revealed that INDQ/NO induces DNA damage and is a potent inhibitor of cancer cell proliferation.
AuthorsKavita Sharma, Aishwarya Iyer, Kundan Sengupta, Harinath Chakrapani
JournalOrganic letters (Org Lett) Vol. 15 Issue 11 Pg. 2636-9 (Jun 07 2013) ISSN: 1523-7052 [Electronic] United States
PMID23659457 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Aziridines
  • Indolequinones
  • Prodrugs
  • Nitric Oxide
  • NAD(P)H Dehydrogenase (Quinone)
Topics
  • Antineoplastic Agents (chemistry, pharmacology)
  • Aziridines (chemical synthesis, chemistry)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Drug Design
  • Humans
  • Indolequinones (chemical synthesis, chemistry, pharmacology)
  • NAD(P)H Dehydrogenase (Quinone) (chemistry, metabolism, pharmacology)
  • Nitric Oxide (chemistry, metabolism, pharmacology)
  • Prodrugs (chemical synthesis, chemistry)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: